Vancouver

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing. The goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.

Researchers are evaluating zanidatamab combined with chemotherapy to treat people with early-stage HER2-positive breast cancer. This Phase 2 study focuses on patients with Stage II or III invasive breast carcinoma that is confirmed to be HER2-positive. The purpose is to assess the safety and effectiveness of this combination treatment before surgery. Participants receive zanidatamab and chemotherapy drugs such as paclitaxel, docetaxel, carboplatin, trastuzumab, and pertuzumab, all administered intravenously. After completing neoadjuvant therapy, participants agree to undergo either a mastectomy or breast-conserving surgery. The study is open-label and conducted at multiple centers. During the study, researchers monitor the participants' response by measuring the number who achieve a pathological complete response within 8 months. They also ensure participants have adequate organ function, track heart function with imaging, and evaluate treatment safety. Participants are regularly assessed to support study goals and monitor any side effects.

Researchers are evaluating the effectiveness and safety of ACR-368 alone or combined with ultra-low dose gemcitabine (ULDG) sensitization in people with endometrial cancer. This is an open-label Phase 2 study involving participants with high-grade endometrial adenocarcinoma. Participants are grouped based on a test called OncoSignature, which predicts sensitivity to ACR-368, or by tumor subtype without requiring the test. Participants in Arm 1 and Arm 4 receive ACR-368 as a single treatment, while those in Arms 2 and 3 receive ACR-368 combined with ULDG sensitization. Arms 1 and 2 are for participants selected by OncoSignature status, while Arms 3 and 4 include participants with serous carcinoma regardless of OncoSignature results. Treatment continues until the disease progresses, unacceptable side effects occur, or the participant withdraws. Participants will have tumor response assessed every 8 weeks from the start of treatment through two years or until death. To join, participants must have measurable metastatic cancer that progressed after prior therapies, provide tumor tissue samples, and meet health and organ function requirements. Safety and response will be closely monitored throughout the study.

Researchers are evaluating the maximum tolerated dose and safety of Anvumetostat, a PRMT5 inhibitor, given in combination with other therapies for adults with metastatic or locally advanced gastrointestinal, biliary tract, or pancreatic cancers that have a specific genetic deletion called homozygous MTAP-deletion. This phase 1b study aims to find the recommended dose while monitoring safety and tolerability in these patients. Participants will receive Anvumetostat orally along with other treatments including gemcitabine and nab-paclitaxel given intravenously, modified FOLFIRINOX (a combination of irinotecan, 5-FU, leucovorin, and oxaliplatin given IV), or RMC-6236 taken orally. The study includes different subprotocols for patients based on their cancer characteristics and previous treatments. Treatment schedules and combinations are carefully evaluated to determine the best dosing. During the study, participants will be closely monitored for side effects such as dose limiting toxicities, treatment emergent adverse events, and serious adverse events for up to about two years. Researchers will assess organ function, tumor response using RECIST criteria, and overall safety. The study involves tumor biopsies or archival tissue samples and various clinical assessments throughout the treatment and follow-up periods to ensure comprehensive evaluation of the drug combinations.

Researchers are evaluating alisertib monotherapy in patients with extensive stage small cell lung cancer (SCLC) who have already undergone treatment with a platinum-based chemotherapy and an anti-PD-L1 immunotherapy. This Phase 2 study aims to identify biomarker-defined subgroups that might benefit most from alisertib and to assess the drug's effectiveness, safety, and how it is processed by the body. Participants may have received up to two prior systemic anti-cancer therapies for SCLC. The study involves giving patients alisertib in the form of enteric-coated tablets. The study focuses on a specific group of patients who have progressed after previous treatments. There are no details provided about dosing schedules or additional treatment periods within the source. During the study, researchers will measure outcomes such as objective response rate, duration of response, disease control rate, progression-free survival, and overall survival, all assessed within biomarker-defined subgroups up to 36 months from the first dose. Participants will be monitored throughout this period to evaluate these outcomes and to observe safety and pharmacokinetics.

The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC; that is one of the major types of lung cancer).

Researchers are evaluating the efficacy and safety of a drug called azenosertib (ZN-c3) in women with platinum-resistant, high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. This Phase 2 study focuses on patients whose tumors test positive for Cyclin E1 protein, determined by a specific assay developed by the sponsor. The study aims to understand how well azenosertib works in this group and its safety profile. The study involves administering azenosertib orally to participants. It is divided into two parts: Part 1 included all patients regardless of biomarker status and has completed enrollment; Part 2 requires tumors to be Cyclin E1 positive. Participants receive azenosertib and are monitored throughout the study according to the protocol. Participants will be involved in various assessments including tumor measurements following RECIST version 1.1 criteria up to about 12 months after the last participant enrolls. Researchers will track the objective response rate to evaluate tumor response. Safety and efficacy evaluations, along with monitoring of side effects and overall health, will take place during the study period to gather comprehensive data on the treatment.

Researchers are evaluating the effectiveness of adding LY3537982 (olomorasib) to standard anti-cancer drugs compared to standard treatment alone in participants with untreated advanced non-small cell lung cancer (NSCLC) that has a specific KRAS G12C gene mutation. This pivotal Phase 3 trial includes participants with locally advanced or metastatic NSCLC and considers their programmed death-ligand 1 (PD-L1) expression levels. The study includes multiple parts: Dose Optimization, Part A, and Part B are randomized, while Safety Lead-In for Part B and Part C are non-randomized. Treatments being assessed include LY3537982 taken orally, pembrolizumab administered intravenously, and standard chemotherapy drugs such as cisplatin, carboplatin, and pemetrexed given intravenously. Participants receive these treatments according to their assigned groups based on their PD-L1 expression and tumor histology. Participants will be monitored with regular assessments including measuring disease progression, safety evaluations, and treatment emergent adverse events for up to approximately one year, with overall study participation potentially lasting up to three years depending on individual response and health status. Outcome measures focus on progression-free survival and safety, capturing any adverse events from the start of treatment until disease progression or death.

Researchers are evaluating the safety and effectiveness of ifinatamab deruxtecan (I-DXd) combined with the immune checkpoint inhibitor atezolizumab, with or without carboplatin, in adults with extensive stage-small cell lung cancer (ES-SCLC). This study includes two parts: Part A, a Phase 1b safety run-in phase, and Part B, a Phase 2 dose optimization phase. The main goal is to assess treatment-related side effects and determine the best dose of I-DXd in these combination therapies for first-line treatment. The study has two cohorts: Cohort 1 includes participants receiving I-DXd as maintenance therapy after initial induction treatment with carboplatin, etoposide, and atezolizumab; Cohort 2 includes participants receiving I-DXd during both induction and maintenance phases without prior ES-SCLC treatment. All study drugs, including I-DXd, atezolizumab, and carboplatin, are given intravenously. Participants will receive treatments in cycles of 21 days, with specific dosing and combination regimens evaluated during the study. Participants will undergo regular assessments including monitoring for dose-limiting toxicities and any treatment-emergent adverse events from the start of treatment up to 37 months. Safety evaluations, laboratory tests, imaging, and other study procedures will be conducted according to the protocol. The study aims to closely observe how participants tolerate the treatments and to collect important data on side effects and overall safety throughout the study period.

Researchers are evaluating the effectiveness and safety of opevesostat combined with hormone replacement therapy compared to alternative treatments with abiraterone acetate or enzalutamide in people with metastatic castration-resistant prostate cancer (mCRPC) who have already been treated with one next-generation hormonal agent. This Phase 3 study aims to determine whether opevesostat improves radiographic progression-free survival, assessed by independent central review, in participants with or without androgen receptor ligand binding domain mutations. Participants will receive either oral opevesostat along with hormone replacement therapy drugs such as dexamethasone and fludrocortisone acetate, or they will receive alternative oral treatments including abiraterone acetate with prednisone acetate or enzalutamide. Hydrocortisone can be used as a rescue drug if needed. The study is open-label and randomized, comparing these treatment strategies in participants who have progressed after prior hormonal therapy. During the study, participants will undergo assessments including imaging scans to monitor disease progression. Researchers will measure radiographic progression-free survival up to approximately 52 months. Safety and overall survival are also monitored as secondary outcomes. Participants must attend scheduled visits for evaluations, provide tumor tissue samples, and have ongoing monitoring of organ function, hormone levels, and other relevant health parameters throughout the study period.